The window of opportunity opens wider for Ascendis

Long-term results are in, and Ascendis Pharma can make the case that its Transcon PTH could become a new treatment for adults with hypoparathyroidism. The pressure is now on the Danish group to move quickly to take advantage of a fortuitous window of opportunity.